Two Sigma Advisers
TCRX icon

Two Sigma Advisers’s TScan Therapeutics TCRX Stock Holding History

Two Sigma Advisers’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-353,900
Closed -$354K – 1913
2025
Q4 		$354K Buy
353,900
+65,100
+23% +$94.2K ﹤0.01% 1921
2025
Q3 		$526K Buy
288,800
+74,400
+35% +$132K ﹤0.01% 1745
2025
Q2 		$311K Buy
214,400
+165,400
+338% +$239K ﹤0.01% 1944
2025
Q1 		$67.6K Buy
+49,000
New +$106K ﹤0.01% 2289
2021
Q4 		– Sell
-13,000
Closed -$108K – 2805
2021
Q3 		$108K Buy
+13,000
New +$121K ﹤0.01% 2319

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Two Sigma Advisers's TCRX Position: Q1 2026 in Review

Two Sigma Advisers sold out of TScan Therapeutics (TCRX) in Q1 2026, closing a stake of 353,900 shares — an estimated $354K sold.

Two Sigma Advisers first reported a position in TCRX in Q3 2021 and held it in 5 quarters. The position peaked at $526K in Q3 2025. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • Two Sigma Advisers reported no remaining TScan Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 353,900 TScan Therapeutics shares in Q1 2026, an estimated $354K.
  • Two Sigma Advisers first reported a position in TScan Therapeutics in Q3 2021 and held it in 5 quarters.
  • Two Sigma Advisers's TScan Therapeutics position peaked at $526K in Q3 2025.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.